µÏÍþ¹ú¼Ê

µÏÍþÖƵÏÍþ¹ú¼Ê µÏÍþÖƵÏÍþ¹ú¼Ê

¼ò ¤™
  • ¼ò
  • ·±
  • EN
¤œ
Ïà¹ØÁ´½Ó
  • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
ÐÂÎÅ·¢²¼
Press Release
Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
µÏÍþÖƵÏÍþ¹ú¼Ê | °¢ÃÀÀÖ?µÚÈýÏîÊÊÓ¦Ö¢»ñÅúÉÏÊУ¬ÓÃÓÚ¢óÆÚ²»¿ÉÇÐNSCLC»¼Õß·Å»¯ÁƺóµÄά³ÖÖÎÁÆ
·¢²¼ÈÕÆÚ£º2025/03/10
×ÖºÅ

2025Äê3ÔÂ10ÈÕ£¬µÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£¬03692.HK£©Ðû²¼£¬°¢ÃÀÀÖ?£¨¼×»ÇËá°¢ÃÀÌæÄáƬ£©ÐÂÊÊÓ¦Ö¢»ñÅúÉÏÊУ¬ÓÃÓÚº¬²¬¸ùÖÎÐÔ·Å»¯Áƺóδ³öÏÖ¼²²¡½øÕ¹µÄ²»¿ÉÇгýµÄ¾Ö²¿ÍíÆÚ±íƤÉú³¤Òò×ÓÊÜÌ壨EGFR£©ÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äµÄ·ÇСϸ°û·Î°©£¨NSCLC£©»¼ÕßµÄÖÎÁÆ£¬´ËΪ°¢ÃÀÀÖ?ÉÏÊÐ5ÄêÀ´»ñÅúµÄµÚÈýÏîÊÊÓ¦Ö¢¡£¾Ý´Ë£¬°¢ÃÀÀÖ?³ÉΪĿǰΨһ»ñÅúÓÃÓÚ¢óÆÚ²»¿ÉÇÐNSCLC»¼Õß·Å»¯Áƺóά³ÖÖÎÁƵÄÖйúÔ­ÑÐÈý´úEGFR-TKI¡£


±¾´Î»ñÅúÖ÷Òª»ùÓÚPOLESTAR£¨HS-10296-304£©Ñо¿£¬ÕâÊÇÒ»ÏîËæ»ú¡¢Ë«Ã¤¡¢¶ÔÕÕ¡¢¶àÖÐÐĵĢóÆÚÁÙ´²Ñо¿£¬ÓÉɽ¶«Ê¡Ö×ÁöÒ½ÔºÓÚ½ðÃ÷Ժʿ×÷ΪÖ÷ÒªÑо¿ÕßǣͷÍê³É¡£Ñо¿½á¹ûÔøÈëÑ¡2024ÄêÊÀ½ç·Î°©´ó»á£¨WCLC£©¡°×îÐÂÍ»ÆÆÕªÒª£¨Late Breaking Abstract£¬LBA£©¡±Ãûµ¥£¬²¢ÒÔ¿ÚÍ·±¨¸æµÄÐÎʽÔÚ´ó»áµÄÖ÷ϯÂÛ̳ÉϳÊÏÖ¡£

Ñо¿½á¹ûÏÔʾ£¬°¢ÃÀÀÖ?½«¼²²¡½øÕ¹·çÏÕ½µµÍÁË80%ÒÔÉÏ£»½ÓÊÜ°¢ÃÀÀÖ?ÖÎÁƵĻ¼ÕßÖÐλÎÞ½øÕ¹Éú´æÆÚ£¨mPFS£©Îª30.4¸öÔ£¬¶ø½ÓÊÜ°²Î¿¼ÁÖÎÁƵĻ¼ÕßmPFS½öΪ3.8¸öÔ£¬ÇÒ°¢ÃÀÀÖ?¸÷Ô¤ÉèÑÇ×éPFS»ñÒæÒ»Ö£¬³ÊÏÖÈ«Ãæ»ñÒæÈËȺµÄÌØÕ÷¡£´ËÍ⣬BICRÆÀ¹ÀµÄ°¢ÃÀÀÖ?ÖÎÁÆ×黼ÕߵĿ͹ۻº½âÂÊ£¨ORR£©´ï57%£¬ÖÐλ»º½â³ÖÐøʱ¼ä£¨DoR£©ÑÓ³¤ÖÁ16.59¸öÔ£¬ÖÐλ×ÜÉú´æÆÚ£¨OS£©ÉÐδ´ïµ½£¬CNS²¡±äºÍÔ¶´¦×ªÒÆ·¢ÉúÂʸüµÍ¡£·Å»¯Áƺó°¢ÃÀÀÖ?ÖÎÁÆ×黼ÕßµÄ×ÜÌåÄÍÊÜÐÔÁ¼ºÃÇҿɹÜÀí£¬ÔÚ²»Á¼Ê¼þ£¨AE£©ÖУ¬¡Ý3¼¶·ÅÉäÐÔ·ÎÑ×·¢ÉúÂÊΪ0£¬¼äÖÊÐÔ·ÎÑ×·¢ÉúÂÊΪ0¡£

Æù½ñΪֹ£¬°¢ÃÀÀÖ?ÒÑÓÐÈýÏîÊÊÓ¦Ö¢»ñÅúÉÏÊУ¬ÆäÖÐÇ°Á½ÏîÓÚ2024Äê11ÔÂÐøÔ¼ÄÉÈë2024°æ¹ú¼ÒÒ½±£Ä¿Â¼£»ÁíÓÐÁ½ÏîÊÊÓ¦Ö¢ÉÏÊÐÉêÇ루NDA£©ÒÑ»ñÊÜÀí£º


»ñÅúÉÏÊУº¶þÏßÖÎÁÆ

¼ÈÍù¾­EGFR-TKIÖÎÁƽøÕ¹£¬ÇÒT790MÍ»±äÑôÐԵľֲ¿ÍíÆÚ»òתÒÆÐÔNSCLC»¼Õß

»ñÅúʱ¼ä£º2020Äê3ÔÂ


»ñÅúÉÏÊУºÒ»ÏßÖÎÁÆ

¾ßÓÐEGFRÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äÑôÐԵľֲ¿ÍíÆÚ»òתÒÆÐÔNSCLC³ÉÈË»¼ÕßµÄÒ»ÏßÖÎÁÆ

»ñÅúʱ¼ä£º2021Äê12ÔÂ


»ñÅúÉÏÊУºÎ¬³ÖÖÎÁÆ

º¬²¬¸ùÖÎÐÔ·Å»¯Áƺóδ³öÏÖ¼²²¡½øÕ¹µÄ²»¿ÉÇгýµÄ¾Ö²¿ÍíÆÚ±íƤÉú³¤Òò×ÓÊÜÌ壨EGFR£©ÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äµÄ·ÇСϸ°û·Î°©£¨NSCLC£©»¼ÕßµÄÖÎÁÆ

»ñÅúʱ¼ä£º2025Äê3ÔÂ


NDA»ñÊÜÀí£ºÊõºó¸¨Öú

¾ßÓÐEGFRÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äÑôÐÔµÄNSCLC³ÉÈË»¼ÕßÖ×ÁöÇгýÊõºóµÄ¸¨ÖúÖÎÁÆ

ÊÜÀíʱ¼ä£º2024Äê7ÔÂ


NDA»ñÊÜÀí£º°Ð»¯ÁªºÏ

ÁªºÏÅàÃÀÇúÈûºÍ²¬À໯ÁƵÏÍþ¹ú¼ÊÎïÊÊÓÃÓÚ¾ßÓÐEGFRÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äµÄ¾Ö²¿ÍíÆÚ»òתÒÆÐÔNSCLC³ÉÈË»¼ÕßµÄÒ»ÏßÖÎÁÆ

ÊÜÀíʱ¼ä£º2024Äê11ÔÂ



¹ØÓڷΰ©


·Î°©ÔÚÖйúÈÔÈ»ÊÇ°©Ö¢·¢²¡ÂʺÍËÀÍöÂʵÄÊ×ÒªÔ­Òò¡£¸ù¾Ý2022ÄêµÄͳ¼ÆÊý¾Ý£¬ÖйúÔ¼ÓÐ106ÍòÐ·ΰ©²¡Àý£¬Õ¼ËùÓжñÐÔÖ×ÁöµÄ22.0%£¬ÓÐ74Íò°©Ö¢Ïà¹ØËÀÍö£¬Õ¼ËùÓа©Ö¢ËÀÍöµÄ28.5%[1]¡£ÆäÖУ¬·ÇСϸ°û·Î°©£¨NSCLC£©ÊÇ×î³£¼ûµÄÀàÐÍ£¬Õ¼ËùÓÐÕï¶ÏµÄ85%[2]¡£EGFRÍ»±äµÄ»¼Õ߶ÔEGFRÀÒ°±ËἤøÒÖÖƼÁ£¨EGFR-TKIs£©ÌرðÃô¸Ð£¬ÕâÊÇÒ»Àà×è¶Ï´Ù½øÖ×ÁöÉú³¤µÄÌض¨ÐźÅͨ·µÄ°ÐÏòÁÆ·¨[3]¡£



¹ØÓÚ°¢ÃÀÀÖ?


×÷ΪÖйúÊ׸öÔ­ÑÐÈý´úEGFR-TKI£¬°¢ÃÀÀÖ?£¨¼×»ÇËá°¢ÃÀÌæÄáƬ£©´´ÐÂÐÔµØÒýÈë»·±û»ù½á¹¹£¬¾ßÓÐÁ¼ºÃµÄÖ¬ÈÜÐÔºÍÎȶ¨ÐÔ£¬ÄܸüºÃµØ͸¹ýѪÄÔÆÁÕÏ£¬ÇÒ²»Á¼·´Ó¦·¢ÉúÂʵÍ¡£Ä¿Ç°£¬°¢ÃÀÀÖ?ÒÑÓÐÈýÏîÊÊÓ¦Ö¢»ñÅúÉÏÊУ¬·Ö±ðÊÇ£º¶þÏßÖÎÁƼÈÍù¾­EGFR-TKIÖÎÁƽøÕ¹£¬ÇÒT790MÍ»±äÑôÐԵľֲ¿ÍíÆÚ»òתÒÆÐÔNSCLC»¼Õߣ¬Ò»ÏßÖÎÁƾßÓÐEGFRÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äÑôÐԵľֲ¿ÍíÆÚ»òתÒÆÐÔNSCLC³ÉÈË»¼Õߣ¬ÒÔ¼°º¬²¬¸ùÖÎÐÔ·Å»¯Áƺóδ³öÏÖ¼²²¡½øÕ¹µÄ²»¿ÉÇгýµÄ¾Ö²¿ÍíÆÚEGFRÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äµÄNSCLC»¼ÕßÖÎÁÆ¡£



¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê


µÏÍþÖƵÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬ÒÔ¡¸³ÖÐø´´Ð£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬Öصã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£½ØÖÁÄ¿Ç°£¬¹«Ë¾ÒÑÉÏÊÐ7¿î´´ÐµÏÍþ¹ú¼Ê£¬ÐγÉÁ˷ḻµÄ²úÆ·¹ÜÏß¡£µÏÍþÖƵÏÍþ¹ú¼ÊÁ¬Ðø¶àÄêλ¾ÓÈ«ÇòÖƵÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖصã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£µÏÍþÖƵÏÍþ¹ú¼ÊÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£

¸ü¶àÐÅÏ¢Çë·ÃÎÊ£º/¡£

²Î¿¼ÎÄÏ×£º

[1] Liu, Y., Chen, H., & Zhou, Q. (2020). Targeted therapies for EGFR-mutant lung cancer: Advances and challenges. Journal of Thoracic Oncology, 15(5), 743-755. https://doi.org/10.1016/j.jtho.2020.01.008

[2] Wang, X., & Li, Y. (2021). Non-small cell lung cancer: Advances in diagnosis and treatment. Chinese Medical Journal, 134(10), 1234-1242. https://doi.org/10.1097/CM9.0000000000001511

[3] Zhang, L., Sun, Y., & Li, Q. (2022). Lung cancer statistics in China: Incidence and mortality. Cancer Research, 82(12), 2303-2310. https://doi.org/10.1158/0008-5472.CAN-22-0453


ÉùÃ÷£º

1¡¢±¾¹«¸æ½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£

2¡¢µÏÍþÖƵÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓúÍ/»òδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬Ò಻¶ÔÈκεÏÍþ¹ú¼ÊÆ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍƼö¡£

3¡¢±¾¹«¸æÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľö¶¨Ó¦¸ù¾Ý»¼ÕߵľßÌåÇé¿ö²¢×ñÕÕµÏÍþ¹ú¼ÊƷ˵Ã÷Êé¡£

4¡¢ÈçÐèÁ˽⹫˾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£



Ç°Õ°ÐÔ˵Ã÷


±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æ丽Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆΪ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖƵÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£

±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄÜ°üÀ¨ÓëµÏÍþÖƵÏÍþ¹ú¼ÊÒµÎñºÍ²úÆ·Ç°¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆںͲßÂÔÏà¹ØµÄÇ°Õ°ÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍƲâÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿Æѧ¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾­¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËغܶ඼ÊǵÏÍþÖƵÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊƲ»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£

µÏÍþÖƵÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖƵÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζ­Ê¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄÇ°Õ°ÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£

¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿